Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa China sub-study of AZD6234 monotherapy in overweight or obese adults
CTR20251720Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lenbelintide in obesity, Overweight, sponsored by AstraZeneca. Started Jun 2025; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20251720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251720.